Showing 4221-4230 of 6805 results for "".
- Study Findings Cast Doubt on Link Between Eczema and Cardiovascular Diseasehttps://practicaldermatology.com/news/study-findings-cast-doubt-on-link-between-eczema-and-cardiovascular-disease/2458151/Despite recent findings to the contrary, a new study in the British Journal of Dermatology has found that eczema is likely not associated with an increase in cardiovascular risk factors or diseases. "In our study, people who reported having atopic dermatitis were not at any
- Cynosure's SculpSure Cleared for Back, Inner and Outer Thighshttps://practicaldermatology.com/news/cynosures-sculpsure-cleared-for-back-inner-and-outer-thighs/2458155/The U.S. Food and Drug Administration (FDA) granted an expanded clearance for Cynosure's SculpSure to treat the back and inner and outer thighs. The SculpSure treatment is already FDA-cleared for treatment of the abdomen an
- Some Hair Products May Up Breast Cancer Risk in Certain Womenhttps://practicaldermatology.com/news/some-hair-products-may-up-breast-cancer-risk-in-some-women/2458156/Use of hair dyes may increase risk for breast cancer among certain women, new research suggests. Specifically, dark brown or black hair dye was associated with a 51 percent increased overall risk of developing breast cancer among African American women, and a 72 percent increased risk of
- FDA Warns Public About Black Henna Tattoo Riskshttps://practicaldermatology.com/news/fda-warns-public-about-black-henna-tattoo-risks/2458159/Black henna temporary tattoos can cause serious skin reactions, the US Food and Drug Administration (FDA) warns. For centuries, traditional henna, a reddish-brown plant extract, has been used to dye skin, hair, and fingernails in parts of Asia and Northern Africa. Henna is
- HED Research Fuels Understanding of Male Pattern Baldnesshttps://practicaldermatology.com/news/hed-research-fuels-understanding-of-male-pattern-baldness/2458162/The origins of hypohidrotic ectodermal dysplasia (HED) may help researchers get a better handle on the genetic underpinnings of common hair disorders. The findings appear in Nature Communications. About one in 5,000 to 10,000 people are thought to have HED, although this
- Murad Adds Two New Blemish-busting Products for Acne Awareness Monthhttps://practicaldermatology.com/news/murad-adds-two-new-products-for-acne-awareness-month/2458161/June is acne awareness month, and Murad is rolling out two anti-acne new products to help patients say goodbye to blemishes. The new Pore Extractor Pomegranate Mask ($38 from Murad.com) features volcanic clay, pomegranate extract and lactic aci
- Game Change: New Handheld Tissue Scanner Can See Below Surface of Skin in Psoriasishttps://practicaldermatology.com/news/game-change-new-handheld-tissue-scanner-looks-below-surface-of-skin-in-psoriasis/2458166/A new handheld tissue scanner allows dermatologists to look below the surface of skin in psoriasis patients and can provide clinically relevant information, such as the structure of skin layers and blood vessels, without the need for contrast agents or radiation exposure. A team of r
- Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumabhttps://practicaldermatology.com/news/sun-pharma-announces-us-fda-filing-acceptance-of-biologics-license-application-for-tildrakizumab/2458175/The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The
- BERG and debra of America Partner to Raise Awareness of EBhttps://practicaldermatology.com/news/berg-and-debra-of-america-partner-to-raise-awareness-of-eb/2458184/Biopharmaceutical company BERG and the non-profit patient advocacy group Dystrophic Epidermolysis Bullosa Research Association of America (debra of America) are partnering up to help patients and families affecte
- Fibrocell to Continue Phase 1/2 Clinical Trial of FCX-007 for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fibrocell-to-continue-phase-12-clinical-trial-of-fcx-007-for-recessive-dystrophic-epidermolysis-bullosa/2458193/Fibrocell Science, Inc.’s Data Safety Monitoring Board (DSMB) has recommended continuation of the Phase 1/2 clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), following a review of safety data from the first patient treated. No product-re